| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 25.0 | 59.3 | 30.4 |
| Total income | 1400.0 | 1413.0 | 1177.0 |
| Net profit | 274.0 | 260.0 | 233.0 |
| Operating margin | 25.6% | 24.1% | 26.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +17.60% |
|---|---|
| Net profit, quarter on quarter | +5.40% |
BSE results filing, NSE: AJANTPHARM. Figures extracted from the filing.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,557.50
- Market cap
- ₹44,454 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.2×Sector 49.8×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.
Ajanta Pharma Share Pledge
Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.
Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
- Call
- Guides 18% growth
Ajanta Pharma Employee Stock Options
Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.
Ajanta Pharma Dividend
Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.